Advertisement
Journal Home
Search for

Volume 40, Issue 12, Pages 1699-1705 (December 2009)


View previous. 10 of 27 View next.

IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue☆☆

Rebecca L. King, MDCorresponding Author Informationemail address, Theresa Pasha, BS, Michele R. Roullet, MD, Paul J. Zhang, MD, Adam Bagg, MD

Received 12 February 2009; received in revised form 24 April 2009; accepted 5 May 2009. published online 21 August 2009.

Summary 

IMP-3 is a member of the insulin-like growth factor II mRNA binding protein (IMP) family of proteins that play a role in RNA trafficking and stabilization and cell growth and migration during embryogenesis but which are down-regulated in adult tissue. However, IMP-3 has recently been shown to be overexpressed in several epithelial malignancies, with increased expression correlating with aggressive behavior. To our knowledge, there is no published literature evaluating IMP-3 in lymphoid tissue. Accordingly, we immunohistochemically evaluated IMP-3 expression in normal lymphoid tissue and 141 lymphoid neoplasms. Physiologically, IMP-3 expression was restricted to germinal center B cells. Among lymphoid neoplasms, Hodgkin lymphoma demonstrated the highest percentage of positive cases (26/26, 100%) often with bright staining. Burkitt lymphoma was positive in 10 (83%) of 12 cases with moderate to bright staining. Although follicular lymphoma was also positive in a high percentage of cases (12/15, 80%), the intensity was exclusively weak to moderate. Although 22 (85%) of 26 of diffuse large B-cell lymphomas were positive for IMP-3, there was wide variability in staining intensity, which did not correlate with classification into activated B cell versus germinal center B origin. By contrast, lower proportions (8%-20%) of other non–germinal center B lymphoma subtypes were IMP-3–positive. In conclusion, although IMP-3 expression is seemingly restricted to physiologic germinal center B cells, its expression in lymphomas of germinal center B origin is less robust. However, there does appear to be some association with the latter group of lymphomas, which may prove to have diagnostic or therapeutic relevance as the biologic role of IMP-3 is further elucidated.

Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA

Corresponding Author InformationCorresponding author.

 Support: A.B. is supported by a SCOR grant from the Leukemia and Lymphoma Society of America.

☆☆ Disclosure/conflicts of interest: the authors state that they have no conflicts of interest to disclose.

PII: S0046-8177(09)00164-6

doi:10.1016/j.humpath.2009.05.003


View previous. 10 of 27 View next.

Advertisement